Page last updated: 2024-08-22

lutetium and everolimus

lutetium has been researched along with everolimus in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ	1
Claringbold, PG; Turner, JH	1

Trials

1 trial(s) available for lutetium and everolimus

Article	Year
NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. Cancer biotherapy & radiopharmaceuticals, 2015, Volume: 30, Issue:6 Topics: Adult; Aged; Everolimus; Female; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Radionuclide Imaging; Treatment Outcome	2015

Other Studies

1 other study(ies) available for lutetium and everolimus

Article	Year
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate. Endocrine-related cancer, 2013, Volume: 20, Issue:6 Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate	2013

Article

Year

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Endocrine-related cancer, 2013, Volume: 20, Issue:6

Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate

2013